SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma
© Li et al.; licensee BioMed Central Ltd. 2013
Received: 29 October 2012
Accepted: 14 December 2012
Published: 1 March 2013
Synovial sarcoma, X breakpoint 2 interacting protein (SSX2IP), which has been identified as an acute myeloid leukemia associated antigen, is a potential target for leukemia immunotherapy. In rodents, its homologous gene, ADIP, plays an important role in the regulation of cell adhesion and migration, underlying its potential role in promoting metastasis of other cancers.
To investigate the correlation between the expression level of SSX2IP and the clinicopathologic factors of hepatocellular carcinoma (HCC), 53 cases were studied by qPCR and statisted. To directly testing SSX2IP’s contribution to HCC in animal models, 45 nude mice were enrolled in peritoneal spreading and liver metastasis models. For the migration and invasion assays, cell culture experiments were performed using QCMTM 24-Well Colorimetric Migration Assay Kit and Cell Invasion Assay Kit (Millipore). Moreover we examined the influence of SSX2IP overexpression on the chemosensitivity of hepatocellular carcinoma cells to two most common chemotherapy drugs (5-Fu and CDDP) using Cell counting kit-8 (CCK-8). The chemotherapeutic drugs sensitivity was evaluated by IC50 parameter.
Statistical analysis of clinical cases revealed that the SSX2IP high expression group had inclinations towards larger tumor size, more tumor thrombus and shorter survival period, implying a strong correlation between the expression level of SSX2IP and HCC tumorigenesis. Consistently in abdominal cavity metastasis and liver metastasis models of immune-deficient mice, SSX2IP was able to promote the metastasis of hepatoma cells. At the cytological level, SSX2IP stimulates the wound healing, metastasis and invasion of hepatoma cells, and reduces the sensitivity of hepatoma cells to 5-Fu and CDDP.
Our results showed that SSX2IP promotes the development and metastasis of hepatocellular carcinoma and contributes to the drug resistance of hepatoma cells, suggesting that SSX2IP is expected to become a new diagnostic and prognostic marker and a new target of the treatment of hepatocellular carcinoma.
KeywordsSSX2IP Hepatocellular carcinoma Metastasis Chemotherapeutic resistance
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, ranking the fifth of the global malignant tumor incidence and the third of cancer related cause of death[1, 2]. In China, hepatocellular carcinoma incidence ranks second only to lung cancer and counts for about half of the global number, thus people’s health and life quality have been seriously affected. As the disease symptom is not obvious, early diagnosis is difficult; most of the patients have advanced cancer at the time of diagnosis, and the disease is easy to relapse even if the lesions were resected. Although chemotherapy is an important method in combined treatment of hepatocellular carcinoma, its effect becomes less unsatisfactory as hepatoma cells from advanced cancer often develop resistance to chemotherapeutic drugs. Therefore, identifying molecular markers suitable for early diagnosis and new therapeutic targets for treatment will greatly benefit the many HCC patients around the world.
The SSX2IP gene is located on chromosome 1p22.3, spanning 46 kb region and containing 14 exons. The locus has a higher frequency of deletions, amplifications and translocations[4–6]. SSX2IP was originally identified through its interaction with SSX2, a transcriptional repressor, and was suggested to regulate the role of SSX2 in testicular tissue and malignant cells. Previous studies indicated that SSX2IP is an acute myeloid leukemia-associated antigen, as analysis of clinical cases showed that the expression of SSX2IP was identified in the serum of 33% patients with acute myeloid leukaemia (AML), but not in healthy volunteers. SSX2IP expression was most apparent on the surface of myeloid leukaemia cells in mitosis[10, 11]. Several studies further strengthened the argument that SSX2IP was an acute myeloid leukemia-associated antigen and a potential immunotherapy target for leukemia[12–14]. So far, the role of SSX2IP in other human tumors remains elusive.
Afadin DIL domain-interacting protein (ADIP) is the homologous gene of SSX2IP in rodents, and the amino acid sequences of ADIP in mouse and rat show 88% and 87% identity with SSX2IP respectively. Cytologically, ADIP localizes at cell-cell adherens junctions and promotes cell migration by activating Rac protein through Vav2[15, 16]. All of the above characteristics are closely related to the adhesion capacity and metastatic characteristics. Given the functionality prompts of SSX2IP and its homologue gene ADIP, we decided to explore the role of SSX2IP in the development and progression of hepatocellular carcinoma.
Cell culture and transfection
Human hepatocellular carcinoma cell lines SMMC-7721 and BEL-7402 were preserved in our institute. Briefly, cells were grown in DMEM supplemented with 10% fetal calf serum. Cells were maintained at 37°C with 5% CO2. SSX2IP was constructed into pEGFP-C1 eukaryotic expression vector. We obtained stably transfected clones by G418 selection (Promega, 800 μg/ml). A stable transfectant of the pEGFP-C1 empty vector was used as a control.
Migration, invasion and scratch wound healing assays
For the cell migration assays, cell culture was performed using QCMTM 24-Well Colorimetric Migration Assay Kit (Millipore) according to the manufacturer’s instructions. For the invasion assay, Cell Invasion Assay Kit (Millipore) was used according to the manufacture’s instructions. Cells (1 × 105) in 300 μl serum-free medium were added to the upper chambers and cultured for 48 h. Non-migrating or non-invading cells were removed with cottons swabs, Cells that migrated or invaded to the bottom of the membrane were stained with the cell stain buffer provided in the assay kit and counted under microscope and photographed. Three independent experiments were performed for the same conditions. For the scratch wound healing assay, cells were cultured in serum-free medium for 24 h and wounded with pipette tips. Fresh medium was replaced. The wound closing procedure was observed for 48 h, and photographs were taken every 24 h.
Nude mice study
Both peritoneal spreading and liver metastasis models were observed. 4-week-old male BALB/C nude mice were purchased from the Institute of Zoology, Chinese Academy of Sciences of Shanghai. All experiments were performed in accordance with the official recommendations of the Chinese animal community. In peritoneal spreading experiment, 5 mice were enrolled in each group. 1 × 106 cells of BEL-7402, BEL-7402Vector and BEL-7402SSX2IP were injected into each mouse. In liver metastasis study, 10 mice were enrolled in each group. 1 × 106 cells of BEL-7402, BEL-7402Vector and BEL-7402SSX2IP were injected into caudal vena. 6 weeks after intraperitoneal injection, mice were killed by cervical decapitation, the abdominal masses were excised and fixed with buffered formalin for further morphological analysis. 10 weeks after caudal vena injection, mice were killed by cervical decapitation. The liver of mice was examined carefully and the metastatic masses were counted.
Chemotherapeutic drugs sensitivity analysis by cell counting kit-8
Hepatocellular carcinoma cells (3 × 103 cells/well) were seeded in 96-well plates and treated with different chemotherapeutics 5-fluorouracil (5-Fu) and Cis-diamminedichloroplatinum (CDDP) in different concentrations for 72 h. Cell Counting Kit-8 (CCK-8, Dojindo, Japan) was added into each well. After 4 h incubation at 37°C, the coloring reaction was quantified by an automatic plate reader (BIO.TEK, USA). Growth inhibitory effects were expressed as cell viability curve (OriginPro 8.5.1, USA). The chemotherapeutic drugs sensitivity was evaluated by IC50 parameter (inhibitory concentration of 50% cells).
HCC tissues were collected from patients at Zhongshan Hospital, Fudan University, after obtaining the subjects’ informed consent and with institutional review board approval of the hospital.
mRNA expression analysis
Total RNA was extracted using Trizol solution (Invitrogen). Reverse transcription was performed according to the manufacturer’s instructions (Promega). qPCR was performed in triplicate using the SYBR Green Mastermix on the ABI Prism 7900 Sequence Detection System (Applied Biosystems). qPCR primers used as follows: SSX2IP: 5’-CCGGGGAACTAAGCAGAGAGA-3’(Forward), 5’-GTTCATGGTCTTGTCGTGAGAT-3’(Reverse); GAPDH: 5’-GCACCGTCAAGGCTGAGAAC-3’(Forward), 5’-ATGGTGGTGAAGACGCCAGT-3’ (Reverse).
Data were shown as mean ± SD. Statistically significant differences were analyzed using Student t test, when there were only two groups, multiple comparisons were performed by one-way analysis of variance. For survival analysis, Kaplan-Meier method was used. Log rank test was used to analyze differences between statistical significances. All statistical analyses were performed using the SPSS 13.0 software (SPSS Inc, Chicago, IL, USA). P < 0.05 was considered statistically significant.
The expression levels of SSX2IP in HCC patients were significantly correlated with tumor size, tumor thrombosis and survival time
Relationship between SSX2IP expression level and clinicopathologic variables in 53 HCC patients
SSX2IP expression level
Low (n = 21)
High (n = 32)
Lymph node invasion
SSX2IP promotes peritoneal spreading and liver metastasis of hepatocellular carcinoma cells in nude mice
Animal experiments for peritoneal spreading
Cell numbers of injection
1 × 106
2.6 ± 0.89
P < 0.001
1 × 106
2.4 ± 1.14
1 × 106
6.2 ± 0.84
Animal experiments for liver metastasis
Cell numbers of injection
No. of metastasis mice/No. of mice injected
1 × 106
1 × 106
P = 0.023
1 × 106
SSX2IP enhances scratch wound healing ability of hepatocellular carcinoma cells
SSX2IP promotes migration and invasion of hepatocellular carcinoma cells
SSX2IP reduces the sensitivity of hepatocellular carcinoma cells to chemotherapeutic drugs
Statistical analysis of pathological features and postoperative survival of clinical cases of hepatocellular carcinoma patients demonstrated that tumor with SSX2IP high expression had inclinations towards larger tumor size and more tumor thrombus. Patients with high SSX2IP expression experienced significantly shorter periods of postoperative survival. These data indicated great significance of SSX2IP in the clinical research of hepatocellular carcinoma.
Metastatic ability of hepatoma cells is the key factor for HCC development. In intraperitoneal injection and tail vein injection experiments in nude mice, over-expression of SSX2IP can promote intraperitoneal spreading and formation of liver metastases. In vitro studies, scratch wound healing assay and transwells migration assay have been widely used for studying the motility of tumor cells to reflect their ability to penetrate extracellular matrix and to migrate. Hepatoma cells with high expression of SSX2IP were shown a very strong mobility, and the number of cells which had penetrate the filter membrane in this group was significantly higher than in the parental and empty vector-transfected groups. These results suggest that SSX2IP could promote the migratory and invasive ability of hepatoma cells.
The dynamic changes of cell adhesion characteristics and the reorganization of cytoskeletal play important roles in the process of tumor invasion and metastasis[17, 18]. ADIP, the homologous gene of SXX2IP in rodents, localizes at cell-cell adherent junctions and binds to α-actinin, a kind of F-actin-bundling protein. ADIP may play a key role in the organization of the cytoskeleton at cell-cell adherent junctions and may connect the nectin-afadin and E-cadherin-catenin systems. These systems have been shown to maintain the epithelial to mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET), and studies of a variety of tumors have revealed that this conversion characteristics of the tumor cells is an important reason for the tumor metastasis and recurrence[19–21]. Therefore, it is suggested that SSX2IP may regulate the EMT-MET by affecting E-cadherin-catenin systems and thereby promote the invasion and metastasis of tumor cells.
On the other hand, ADIP has been shown to promote cell movement by regulating the activation of Rac1. Rac1 belongs to the Rho family and the Ras superfamily of small GTP-binding proteins, and it is an important regulator which connects membrane surface receptors and actin cytoskeleton and plays a role of molecular switch. Members of Rho family regulate the actin assembly and affect cell movement, tumor invasion and migration. The guanine nucleotide exchange factor specific to Rac1 can regulate cytoskeleton reorganization, affect cell polarity and promote cell motility and migration by promoting the conversion of Rac-GDP (inactivation) to Rac1-GTP (activation). As our study indicated a role of SSX2IP in promoting the mobility of HCC cells, we speculated that SSX2IP may do so via activating Rac1. We are actively investigating the influence of SSX2IP on Rac1 activation.
Chemotherapy plays an irreplaceable role in the clinical treatment of HCC. However, resistance of hepatoma cells to chemotherapy drugs often makes chemotherapy unsatisfactory. High expression of some resistance related genes in tumor cells is the underlying cause of drug resistance that eventually leads to ineffective treatment. Our data showed SSX2IP reduced the sensitivity of hepatoma cells to 5-Fu and CDDP and significantly increased IC50, which indicated that SSX2IP may be a resistance related gene with the ability to promote the resistance of hepatoma cells to chemotherapeutic drug. Although the exact function of SSX2IP in drug resistance is still unknown, clues can be taken from its rodent homologue ADIP, which directly binds to β’-COP to participate in the vesicle trafficking from the Golgi apparatus to the endoplasmic reticulum. As is well known, many resistance genes encode transporter proteins, such as ABCG2 in the ABC protein family[27, 28]. We speculate that SSX2IP is likely to be a player in the intracellular transportation system.
Studies of SSX2IP in tumor-related fields have been focused on leukemia in the past, while little is known about its role in oncology of other types of cancers. Our results suggest that SSX2IP can significantly promote the motility, invasion and migration of hepatoma cells and improve their resistance to chemotherapeutic drugs. Importantly, since SSX2IP has been identified as an acute myeloid leukaemia-associated antigen and a potential immunotherapy target for leukemia, this study has expanded the usage of those SSX2IP related applications to HCC. Further in-depth exploration of the molecular mechanisms of SSX2IP in promoting the migration, invasion and drug resistance of HCC will be needed to clarify the role of SSX2IP in HCC development and to provide theoretical basis for future clinical applications.
Our studies showed that SSX2IP can promote the development and metastasis of hepatocellular carcinoma. It reduces the sensitivity of hepatocellular carcinoma cells to chemotherapeutic drugs and could be a resistance-associated gene. All the above, our findings suggest that SSX2IP may serve as a new target for clinical diagnosis and treatment of hepatocellular carcinoma.
Synovial sarcoma X breakpoint 2 interacting protein
Afadin DIL domain-interacting protein
Half maximal (50%) inhibitory concentration (IC) of a substance.
We are grateful to Prof. Yinkun Liu (Hepatocellular carcinoma Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China) for sharing the hepatocellular carcinoma samples. This study is supported by grants from the National Science and Technology Key Program of China (2009ZX09301-011) and National Key Basic Research Program of China (2010CB912602, 2013CB531603).
- Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin. 2002, 52: 23-47. 10.3322/canjclin.52.1.23.View ArticlePubMedGoogle Scholar
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.View ArticlePubMedGoogle Scholar
- Maglott D, Ostell J, Pruitt KD, Tatusova T: Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2007, 35: D26-D31. 10.1093/nar/gkl993.PubMed CentralView ArticlePubMedGoogle Scholar
- Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML: DNA copy number losses in human neoplasms. Am J Pathol. 1999, 155: 683-694. 10.1016/S0002-9440(10)65166-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H: DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998, 152: 1107-1123.PubMed CentralPubMedGoogle Scholar
- Cigudosa JC, Parsa NZ, Louie DC, Filippa DA, Jhanwar SC, Johansson B, Mitelman F, Chaganti RS: Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer. 1999, 25: 123-133. 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, Shipley J, Gusterson BA, Cooper CS: Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 1995, 14: 2333-2340.PubMed CentralPubMedGoogle Scholar
- de Bruijn DR, dos Santos NR, Kater-Baats E, Thijssen J, van den Berk L, Stap J, Balemans M, Schepens M, Merkx G, van Kessel AG: The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes Chromosomes Cancer. 2002, 34: 285-298. 10.1002/gcc.10073.View ArticlePubMedGoogle Scholar
- Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, Wells JW, Banham AH, Mufti GJ: Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun. 2005, 335: 1293-1304. 10.1016/j.bbrc.2005.08.024.View ArticlePubMedGoogle Scholar
- Denniss FA, Breslin A, Ingram W, Hardwick NR, Mufti GJ, Guinn BA: The leukaemia-associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cells. Br J Haematol. 2007, 138: 668-669. 10.1111/j.1365-2141.2007.06706.x.View ArticlePubMedGoogle Scholar
- Breslin A, Denniss FA, Guinn BA: SSX2IP: an emerging role in cancer. Biochem Biophys Res Commun. 2007, 363: 462-465. 10.1016/j.bbrc.2007.09.052.View ArticlePubMedGoogle Scholar
- Guinn BA, Bullinger L, Thomas NS, Mills KI, Greiner J: SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. Br J Haematol. 2008, 140: 250-251.PubMedGoogle Scholar
- Guinn B, Greiner J, Schmitt M, Mills KI: Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood. 2009, 113: 1203-1204.View ArticlePubMedGoogle Scholar
- Zhang L, Greiner J: Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia. Immunotherapy. 2011, 3: 697-699. 10.2217/imt.11.50.View ArticlePubMedGoogle Scholar
- Asada M, Irie K, Morimoto K, Yamada A, Ikeda W, Takeuchi M, Takai Y: ADIP, a novel Afadin- and alpha-actinin-binding protein localized at cell-cell adherens junctions. J Biol Chem. 2003, 278: 4103-4111. 10.1074/jbc.M209832200.View ArticlePubMedGoogle Scholar
- Fukumoto Y, Kurita S, Takai Y, Ogita H: Role of scaffold protein afadin dilute domain-interacting protein (ADIP) in platelet-derived growth factor-induced cell movement by activating Rac protein through Vav2 protein. J Biol Chem. 2011, 286: 43537-43548. 10.1074/jbc.M111.308858.PubMed CentralView ArticlePubMedGoogle Scholar
- Sahai E, Marshall CJ: Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 2003, 5: 711-719. 10.1038/ncb1019.View ArticlePubMedGoogle Scholar
- Buccione R, Caldieri G, Ayala I: Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev. 2009, 28: 137-149. 10.1007/s10555-008-9176-1.View ArticlePubMedGoogle Scholar
- Chen J, Han Q, Pei D: EMT and MET as paradigms for cell fate switching. J Mol Cell Biol. 2012, 4: 66-69. 10.1093/jmcb/mjr045.View ArticlePubMedGoogle Scholar
- Vincan E, Barker N: The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis. 2008, 25: 657-663. 10.1007/s10585-008-9156-4.View ArticlePubMedGoogle Scholar
- Thompson EW, Williams ED: EMT and MET in carcinoma-clinical observations, regulatory pathways and new models. Clin Exp Metastasis. 2008, 25: 591-592. 10.1007/s10585-008-9189-8.View ArticlePubMedGoogle Scholar
- Aspenstrom P, Ruusala A, Pacholsky D: Taking Rho GTPases to the next level: the cellular functions of atypical Rho GTPases. Exp Cell Res. 2007, 313: 3673-3679. 10.1016/j.yexcr.2007.07.022.View ArticlePubMedGoogle Scholar
- Mula RV, Bhatia V, Falzon M: PTHrP promotes colon cancer cell migration and invasion in an integrin alpha6beta4-dependent manner through activation of Rac1. Cancer Lett. 2010, 298: 119-127. 10.1016/j.canlet.2010.06.009.PubMed CentralView ArticlePubMedGoogle Scholar
- Nowak AK, Chow PK, Findlay M: Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004, 40: 1474-1484. 10.1016/j.ejca.2004.02.027.View ArticlePubMedGoogle Scholar
- Whang-Peng J, Cheng A-L, Hsu C, Chen C-M: Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental & Clinical Medicine. 2010, 2: 93-103. 10.1016/S1878-3317(10)60016-2.View ArticleGoogle Scholar
- Asada M, Irie K, Yamada A, Takai Y: Afadin- and alpha-actinin-binding protein ADIP directly binds beta’-COP, a subunit of the coatomer complex. Biochem Biophys Res Commun. 2004, 321: 350-354. 10.1016/j.bbrc.2004.06.143.View ArticlePubMedGoogle Scholar
- Mo W, Zhang JT: Human ABCG2: structure, function, and its role in multidrug resistance. International journal of biochemistry and molecular biology. 2012, 3: 1-27.PubMed CentralPubMedGoogle Scholar
- Allen JD, Schinkel AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther. 2002, 1: 427-434. 10.4161/cbt.1.4.25.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.